搜索
Search
这是描述信息

News Center

Homepage
/
Milestones
2024
2024
2024
2025-03-05
Triptorelin Acetate Microspheres for Injection for endometriosis was approved for market release, and Cetrorelix Acetate for Injection was approved for market release by the U.S. FDA.
View details
Triptorelin Acetate Microspheres for Injection for endometriosis was approved for market release, and Cetrorelix Acetate for Injection was approved for market release by the U.S. FDA.
2023
2023
2023
2025-03-05
On May 11, Triptorelin Acetate Microspheres for Injection received a drug registration certificate. On August 1, Livzon was awarded the highest global MSCI ESG rating of AAA.
View details
On May 11, Triptorelin Acetate Microspheres for Injection received a drug registration certificate. On August 1, Livzon was awarded the highest global MSCI ESG rating of AAA.
2022
2022
2022
2022-11-29
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
View details
In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.
2021
2021
2021
2022-04-22
The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
View details
The Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed in collaboration by Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group, has obtained the clinical approval from the National Medical Products Administration, and is currently conducting multi-reginal Phase III clinical trials.
2020
2020
2020
2021-11-16
Corporate culture reform with mission of "Patient Quality of Life Comes First" and vision of "Be the Pharmaceutical Industry Leader"
View details
Corporate culture reform with mission of "Patient Quality of Life Comes First" and vision of "Be the Pharmaceutical Industry Leader"
2016
2016
2016
2021-11-16
Livzon new industrial park completed
View details
Livzon new industrial park completed
2014
2014
2014
2021-11-16
B-share stock transfer to H-share stock
View details
B-share stock transfer to H-share stock
2010
2010
2010
2021-11-16
Focused on the field of biological products, and established monoclonal antibody company
View details
Focused on the field of biological products, and established monoclonal antibody company
Previous page
1
2

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China    Tel： 0756-8135888    

©2021 Livzon  粤ICP备05025993号  Support：300.cn

Add: No.38, Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China  

©2021 Livzon   粤ICP备05025993号  

 Support：300.cn